Kyle also recently retired as a Colonel in the US Army Reserve after 24 years of service. In this role, he will work to evaluate and incubate early-stage therapeutic programs. Sonia has a BA in Chemistry and a PhD in Bioengineering, both from the University of Pennsylvania. Cony D'Cruz is a Venture Partner at RA Ventures. In 2013 was awarded a Medical Research Council Clinical Scientist Fellowship. Prior to this, she served as Director, Talent Acquisition and Operations at Flagship Pioneering, a role in which she built talent systems to support the growth of 30+ pre-series B biotech startup companies. Kathryn Spencer is an Executive Assistant at RA Capital Management. Kolchinsky's mom knew her son was gifted - Boston Business Journal Joel received his doctorate in Organic Chemistry from Columbia University and his bachelors in Chemistry from the University of Pennsylvania. Le Ho is a Business Systems Analyst at RA Capital Management. No Patient Left Behind | Steering committee | Peter Kolchinsky Prior to RA, Laura was a Principal at MP Healthcare Venture Management. Max has a BS in Biology from the State University of New York at Fredonia and a PhD in Cellular and Molecular Biology from the University of Michigan. He holds a Masters degree in Software Engineering from Brandeis University and a BA in Psychology from Providence College. As political refugees, the family was placed in Milwaukee, then Pittsburgh. Nadim Shohdy is an EIR at RA Capital. Matts primary responsibilities at RA Capital are to gather team input to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities, and to provide software training and coordinate with outside technology vendors. Prior to joining RA, Jesse was Senior Director of Discovery at Kymera Therapeutics. Craig is admitted to practice law in the Commonwealth of Massachusetts. Pathways to | Harvard Office of Technology Development Ross has a BS in Biochemistry from University of Oregon and a PhD in Pharmacology & Molecular Sciences from Johns Hopkins University. Senior Research Assistant, Venture Analytics. Sophie is a Fellow of the Royal College of Physicians, London, UK. Anas previous experience includes Research Assistant positions at Massachusetts Eye and Ear Hospital, the Lupus Clinic/Renal Department at the BU Medical Center, and Harvard University Department of Molecular and Cellular Biology. By continuing, you accept the use of these cookies. Neil has spent five years at RA Ventures where he was most recently Vice President, CMC and worked across new company formation and in support of portfolio companies. He worked with Dr. David Raulet and Nobel Laureate Dr. James Allison before which he received a PhD in Molecular Oncology and BSc in Biochemistry from McGill University in Montreal. Monica holds a BSc in Neuroscience and Pharmacology from the University of Toronto and a PhD in Cancer Biology from MIT. Joe brings to RA fifteen years of IT experience, beginning at the Apple Store and then transitioning to Boston Public Schools as an Apple Support Specialist. In his Venture role, Mario is focusing on early-stage investment and company creation. He also supports select RAVen portfolio companies in active strategic operating roles and serves as Board Director for GIVax, Summation Bio, and Astro Therapeutics. Emory Werner is an Associate with the TechAtlas division of RA Capital Management. Abhishek's primary responsibility is to identify needs for process improvement in the firm's data analytics and then both build and implement automated solutions. He holds a MS from Northeastern University and a BA from Hamilton College. He also served as member of the Product Advisory Board at Concert Pharmaceuticals and as an Advisor to Nimbus Therapeutics. Ramaswamy, who just turned 30, has bigger aspirations. Gerald holds a PhD in Molecular and Cellular Biology from Harvard Medical School. Tim was responsible for building the commercial team at GelTex and launching Renagel, a novel treatment for patients with kidney failure that grew to a $1B franchise . Timothy is a veteran biotech leader with deep experience in growing companies and bringing innovative therapies to market. Previously he served as the Director of Pharmaceutical Sciences at the Clinton Health Access Initiative. Kevin has a ME in Chemistry and Chemical Engineering from Chimie ParisTech in France, a MS in Biotechnology from the Royal Institute of Technology in Sweden, and a PhD in Physics and Chemistry from Paris Sciences et Lettres Research University in France. Ed holds a PhD in neuroscience from the University of California Berkeley, an MS in psychology from Villanova University, and a BA from La Salle University. Henrys primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Prior to RA, Drew gained experience in Data Science in Technical Consultant roles at ExxonMobil. Harvey is a Controller at RA Capital Management. Peter Kolchinsky is a father, scientist, investor, teacher, and author. Peter Kolchinsky - RA Capital Management - Insider Monkey Prior to MPM, she worked as an Executive Assistant at Charles River Ventures. James McArthur is an Advisor for RA Capital Management. Tweet With huge thanks to RA Capital's Alex Martinez-Forte and Jacqueline Rhuda for extensive data analysis. Peter Pan & Wendy Movie Review | Common Sense Media He holds a BA in Neuroscience with a minor in Molecular and Cellular Biology from Colorado College. Prior to that, David worked as Director of Operations for Wingspan Investment Management, LP and held operations positions at Brencourt Advisors and Silver Point Capital, LP. Most recently, Brendan served as Tax Director at PwC Asset & Wealth Management. She is a CPA. Adisons primary responsibilities are to coordinate calendars, events, and company meetings for the Investment Team. Ross primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Directed by David Lowery ("The Green Knight") and featuring Law as Captain Hook, the live-action remake leans into the bittersweet coming-of-age theme of J.M. During his four years with Sage, he helped lead the growth of the organization through multiple capital raises, the launch of the companys first product, and execution of a transformational, multi-billion collaboration. Prior to Mirai Advisory, he held a Financial Analyst role at Wainwright Investment Counsel. TipRanks & Hedge Funds: TipRanks measures the performance of Peter Kolchinsky and other hedge fund managers based on information submitted to the SEC. Peter Kolchinsky - Managing Partner - CrunchBase Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Alex has a BS in Chemistry and a Minor in Religious Studies from Davidson College. In his role at Catamaran, he helped secure a Series A financing with a syndicate of leading investors, rapidly recruit an experienced cell therapy team, access enabling technologies, build a broad patent estate, and design external communication strategies. Currently, Dr. Kolchinsky occupies the position of Chairman & Chief Executive Officer of Research Alliance Corp. II (which he founded in 2020) and Managing Partner at RA Capital Management LP (which he founded in 2004), Managing Partner at RA Capital Management LP (Private Equity) (which he founded) (a subsidiary of RA Capital Management LP). Prior to RA, Kevin was a postdoctoral associate at the Broad Institute of MIT and Harvard and an EMBO fellow. Laura previously worked at WinterWyman where she served as a Senior Associate. Chris Caliri is the Chief Information Officer at RA Capital Management. Joey ONeill is an Investor Services Associate at RA Capital Management. His most recent role at Biogen was as Senior Vice President, U.S. Commercial, where he was the general manager of the MS, hemophilia, and SMA franchises. Adam has 20+ years of industry experience in building healthcare and technology companies, including as CEO and co-founder of Link Medicine, a company focused on developing disease-modifying neurodegenerative therapies and as CEO and co-founder of Teleos Therapeutics, an innovative neuroscience drug discovery platform company. He completed the Executive Program at Stanford University, Graduate School of Business, as well as the Executive to Leader Institute at Korn/Ferry International. Prior to joining RA Capital, Jeff worked for over 10 years as an institutional equity sales trader, primarily at KCG Holdings, Inc., where he managed the Boston office. Garrett received a BS with honors from the California Institute of Technology while publishing his first paper with Dr. Paul H. Patterson, holds a PhD in Immunology from Stanford University, where he studied hematopoietic stem and progenitor cells with Dr. Irving L. Weissman, and completed his post-doctoral training at Childrens Hospital Boston/Harvard Medical School studying ES/iPSC specification to the hematopoietic fate with Dr. George Q. Daley.